The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon ...

Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America ...

Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx first quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded ...

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today ...

As many as half are unaware that they have it. These diseases include emphysema and chronic bronchitis. Many people with COPD have both. Emphysema slowly destroys air sacs in your lungs ...

AATD is an inherited disorder whose primary consequence is life-threatening pulmonary emphysema, resulting in irreversible destruction of the tissues supporting the function of the lungs and ...

Air can escape from the area, leaking into the soft tissue of the chest and causing subcutaneous emphysema to form under the skin of the face, neck and chest. A patient may show a rapid onset of ...